Presentation Stuff Flashcards

(60 cards)

1
Q

Prolia: Indication

A

Osteoporosis in men

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Prolia: MOA

A

RANK ligand (RANKL) inhibitor > prevents formation of osteoclasts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prolia: dosing freq

A

one injection q6 mths

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Prolia: route

A

SC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Prolia: Place in tx

A

EDS: used if failed bisphosphonates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Prolia: AEs

A

nasopharyngitis, back pain (bone-related), arthralgia (bone-related)

HTN (less common)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Prolia: cost

A

More than bisphosphonates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Insulin glargine: indication

A

T1/T2DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Insulin glargine: MOA

A

mimics body’s basal insulin release > stimulates glucose uptake and inhibits hepatic glucose production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Insulin glargine: dosing freq

A

qd @ same time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Insulin glargine: route

A

SC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Insulin glargine: AEs

A

nasopharyngitis, URTI, diarrhea, hypoglycemia (less common w/ LA insulins)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Insulin glargine: cost

A

cheaper than Lantus (and more effective than it fyi)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Praluent: indication

A

for familial hypercholesterolemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Praluent: MOA

A

binds to PCSK9 enzymes > reduces degradation of LDL receptors > increased LDL binding and removal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Praluent: route

A

SC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Praluent: place in tx

A

adjunct to high-dose statins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Actemra: indication

A

Rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Actemra: MOA

A

binds IL-6 receptors > inhibits their signalling > reduces inflammation in joints

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Actemra: route

A

IV/SC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Actemra: place in tx

A

EDS:

  1. mod-sev RA as monotx or in combo w/ methotrexate or other DMARDs
  2. failed DMARDs (dz modifying antirheumatic drugs)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Infliximab: indication

A

UC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Infliximab: MOA

A

binds to TNF-a > inhibits its activity > autoimmune response and inflammation are mitigated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Infliximab: route

A

IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Infliximab: place in tx
reserved for pts who've exhaused first-line tx's for their UC
26
Benlysta: indication
systemic lupus erythematosus (i.e. lupus)
27
Benlysta: MOA
binds to B cell stimulator > B cell death > unable to differentiate into plasma cells > reduced Ig production > reduced autoimmune response
28
Benlysta: route
IV/SC
29
Interferon beta-1A: indication
MS (relapsing-remitting MS, high risk of progression to MS)
30
Interferon beta-1A: MOA
blocks action + entry of immune cells > reduced damage to myelin
31
Interferon beta-1A: Place in tx
1st line for pts with relapsing-remitting MS
32
Eylea: indication
Age-related macular degeneration (AMD) > The WET form
33
Eylea: MOA
VEGF decoy inhibitor > intercepts VEGF-A > prevents it from binding to VEGF receptors on blood vessels in the macula > new blood vessels are prevented from growing
34
Eylea: route
intravitreal
35
Eylea: AEs
conjunctival hemorrhage, cataracts, eye pain
36
Eylea: cost
cheaper than ranibizumab, but more expensive than bevacizumab
37
Praxbind: indication
antidote for dabigatran overdose
38
Praxbind: MOA
mAB that binds to dabigatran w/ 300x more affinity than thrombin > creates a complex that gets eliminated
39
Praxbind: administration
two 2.5g bolus doses is given no more than 15 mins apart from e/o
40
Praxbind: route
IV
41
Praxbind: place in tx
ONLY antidote for a NOAC
42
Yervoy: indication
unresectable, metastatic melanoma
43
Yervoy: MOA
mAB that binds and blocks cytotoxic T-lymphocyte antigen 4 (which downregulates the immune sys) > upregulation of the immune system results (cytotoxic T cells, specifically, increase their activity)
44
Gardasil 9: indication
vaccine for HPV (and subsequent cervical, vaginal, vulvar, and anal cancers, as well as genital warts
45
Gardasil 9: MOA
Virus-like particles stimulate immune system > protective Abs against the L1 protein to prevent it from releasing its genetic material
46
Gardasil 9: Dosing
2-3 doses given at 0, 2, and 6 mths
47
Gardasil 9: route
IM
48
Soliris: indication
atypical hemolytic uremic syndrome
49
Soliris: MOA
inhibition of complement sys > reduction of microvascular stress and renal injury
50
Soliris: place in tx
ONLY tx for atypical hemolytic uremic syndrome
51
Omnitrope: indication
tx of growth failure in pediatrics w/ Turner's syndrome (one missing X chromosome in females)
52
Omnitrope: MOA
recombinant human growth hormone > binds to GH receptors on target cell membranes > skeletal growth, cell growth, protein synthesis, metabolic processes
53
Omnitrope: place in tx
standard of care in those w/ GH deficiencies (like Turner syndrome pts)
54
Omnitrope: Why does cost vary?
Because it's weight-based dosing
55
Herceptin: indication
HER2 positive breast cancer
56
Herceptin: MOA
binds extracellular domain of HER2 protein > blocks downstream signaling pathways > inhibits cell proliferation and flags cell for destruction by immune sys
57
Botox: indication
urge incontinence (overactive bladder)
58
Botox: MOA
blocks ACh release at neuromuscular junction > causes paralysis muscle paralysis when injected in detrusor muscle
59
Botox: Dosing
max 4 doses/year at least 12 weeks apart
60
Botox: route
intradetrusor